Get startedLog in
    Picture of Swedish Orphan Biovitrum AB (publ) logo

    SOBI — Swedish Orphan Biovitrum AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: SOBI 2025 Revenue, EBITA Margin Exceed Outlook

    Picture of Swedish Orphan Biovitrum AB (publ) logoSwedish Orphan Biovitrum AB (publ)
    15/01/2026 12:05
    Jan 15 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST:

HIGHER Q4 SALES DRIVE SOBI REVENUE INCREASE

2025 ADJUSTED EBITA MARGIN WAS INCREASED DUE TO HIGHER THAN EXPECTED REVENUE.

2025 ADJUSTED EBITA MARGIN WAS APPROXIMATELY 40% OF REVENUES

FULL YEAR 2025  REVENUE WAS APPROXIMATELY SEK 28.2 BILLION

MAIN REASON FOR INCREASED REVENUE WAS HIGHER THAN EXPECTED Q4 SALES FOR DOPTELET, GAMIFANT AND HAEMOPHILIA PORTFOLIO

Source text: ID:nWkr4MMhxs

Further company coverage: SOBIV.ST

 (Gdansk Newsroom)

 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Swedish Orphan Biovitrum AB (publ)

    See all news